Nuwellis, Inc. reports Q2 2026 revenue of $1.97M, up 14% YoY, with gross margin improving to 76%. Console placements surged, enhancing growth prospects.
Nuwellis, Inc. reported Q2 2026 revenue of $1.97 million, a 14% increase from $1.7 million in Q2 2025 and ahead of the consensus estimate of $1.85 million. The company's strategic focus on expanding its Aquadex platform utilization and penetrating pediatric and critical care markets has begun to yield tangible results, as evidenced by the significant growth in console placements and revenue.
Key Takeaways
- Revenue reached $1.97 million, up 14% YoY, with U.S. revenue increasing 17%.
- Gross margin improved to 76%, up from 56% in Q2 2025, driven by higher average selling prices and favorable product mix.
- Installed base expanded with nine new console placements in Q2 2026, a substantial increase from three in Q2 2025.
- Net loss narrowed to approximately $4.8 million, significantly reduced from $12.6 million in the prior year quarter.
- Cash position strengthened with $12.7 million raised in gross proceeds from financing events, including a $6 million public offering.
Revenue Growth Driven by Console Placements
Nuwellis' revenue for the second quarter of 2026 was $1.97 million, a 14% increase year-over-year, while U.S. revenue rose 17%. The company sold nine consoles during the quarter, compared to three in the same period last year, contributing to the overall revenue growth. The average selling price for U.S. circuits increased by approximately 5%, and console prices rose by about 3%, reflecting pricing adjustments made in the previous year.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $1.97M | +14% | - |
| Gross Margin | 76% | +20pp | - |
| Net Loss | $4.8M | -62% | - |
| Console Placements | 9 | +200% | - |
Strategic Focus on Pediatric and Critical Care Markets
Management emphasized its commitment to expanding in pediatric care and adult critical care, viewing these areas as vital for long-term growth. The company has made significant strides, including expanding into two new states for pediatric programs and enhancing educational initiatives for clinicians. This strategy was illustrated by a case presented at a recent conference, showcasing Aquadex's application in complex pediatric cardiac patients.
Furthermore, Nuwellis plans to broaden its CardioRenal platform through the introduction of new technologies and collaborations, including the anticipated launch of Clarity Prime in 2027, which will monitor kidney function more effectively.
Improved Financial Health and Cost Management
Nuwellis reported a gross profit of approximately $1.5 million for Q2 2026, resulting in a gross margin of 76%, a 20 percentage point improvement year-over-year. This margin expansion was attributed to better pricing and a favorable product mix, alongside the transition to contract manufacturing. Operating expenses rose to approximately $4.7 million, reflecting investments in commercial and product development. However, the company successfully reduced sequential expenses from the prior quarter, indicating improved cost management.
The net loss of approximately $4.8 million represents a significant reduction from the previous year's loss of $12.6 million, showcasing progress in financial discipline. The recent financing efforts have bolstered Nuwellis' cash position, with $12.7 million raised to support ongoing strategic initiatives.
Analyst Q&A Highlights
During the Q&A session, analysts sought clarity on the company's growth strategy and market expansion. Notably, Mike McCormick, the new CEO, reiterated the commitment to enhancing Aquadex's utilization and expanding the installed base. He emphasized the importance of clinical evidence and educational initiatives to drive adoption in pediatric and critical care settings. Analysts from firms like Cantor Fitzgerald and Stifel expressed interest in the long-term financial outlook and the potential impact of product innovations, particularly Clarity Prime.
Frequently Asked Questions
Did Nuwellis, Inc. Common Stock beat earnings estimates in Q2 2026?
Yes, Nuwellis reported Q2 2026 revenue of $1.97 million, exceeding consensus estimates of $1.85 million, representing a 14% year-over-year increase.
What were the console placements in Q2 2026 compared to last year?
Nuwellis sold nine consoles in Q2 2026, a significant increase from three console placements in Q2 2025, reflecting a 200% year-over-year growth.
How did Nuwellis manage its operating expenses in Q2 2026?
Operating expenses rose to approximately $4.7 million in Q2 2026, up from $3.9 million in the prior year quarter, but decreased from $6.3 million in Q1 2026, indicating better alignment with strategic priorities.
What is the expected launch date for Clarity Prime?
The Clarity Prime product, which enhances kidney function monitoring, is expected to launch in 2027, expanding Nuwellis' CardioRenal platform capabilities.
In conclusion, Nuwellis is navigating a critical growth phase under new leadership, focusing on optimizing its product offerings and expanding market reach, particularly in pediatrics and critical care. The strategic initiatives outlined during the earnings call will be pivotal for sustained revenue growth and operational efficiency in the coming quarters.
This analysis is based on public earnings call materials and is not investment advice.
